<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3960188/" ref="ordinalpos=778&amp;ncbi_uid=5992686&amp;link_uid=PMC3960188" image-link="/pmc/articles/PMC3960188/figure/F1/" class="imagepopup">Figure 1. Simplified scheme of mTOR <span class="highlight" style="background-color:">pathway</span> activation.  From: mTOR <span class="highlight" style="background-color:">pathway</span> in colorectal cancer: an update. </a></div><br /><div class="p4l_captionBody">Akt activation releases Rheb from the inhibitory effects of TSC1/2 thus allowing mTOR activation. Signaling defects upstream of mTOR in the PI3K/Akt/mTOR pathway (mutations in PTEN, PI3K, Akt and TSCs) lead to mTOR deregulation. Akt can also be a downstream effector of mTOR, due to mTOR association with different protein partners to form two functionally distinct signaling complexes, mTORC1 and mTORC2.</div></div>